Stockscreener 앱 받기
77.09
0.93%
-0.72
시간 외 거래:
77.09
전일 마감가:
$77.81
열려 있는:
$78.52
하루 거래량:
1.55M
Relative Volume:
0.87
시가총액:
$9.14B
수익:
$1.51B
순이익/손실:
$348.84M
주가수익비율:
27.73
EPS:
2.7805
순현금흐름:
$667.65M
1주 성능:
+1.29%
1개월 성능:
+12.46%
6개월 성능:
+9.46%
1년 성능:
+36.56%
1일 변동 폭
$77.01
$79.04
1주일 범위
$73.89
$79.56
52주 변동 폭
$55.64
$82.26
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
77.09 | 9.23B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 123.26B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.94B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 53.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 39.58B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 35.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations - Contract Pharma
Halozyme enters license agreement with Incyte - The Pharma Letter
Halozyme and Incyte announce global collaboration deal - grafa.com
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development - Yahoo Finance
Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Technology - GuruFocus
Halozyme Therapeutics (HALO) Secures Global Deal with Incyte for Innovative Drug Delivery - GuruFocus
Halozyme partners with Incyte on drug delivery technology By Investing.com - Investing.com Canada
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - PR Newswire
Technical Reactions to HALO Trends in Macro Strategies - Stock Traders Daily
Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics (0J2O) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment - Yahoo Finance
HALO5387960 Bond Profile — Key Metrics - TradingView
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 10% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Halozyme Therapeutics (HALO) Q1 2025 earnings summary - Quartr
Halozyme Therapeutics (HALO) Proxy filing Summary - Quartr
Halozyme Therapeutics (HALO) Q1 2026 earnings summary - Quartr
Halozyme Therapeutics (HALO) AGM 2026 Summary - Quartr
2 Reasons to Like HALO and 1 to Stay Skeptical - Yahoo Finance
Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Cut to $83.44, Implies 6% Upside - TradingView
Halozyme president & CEO Helen Torley sells $153,390 in stock - Investing.com UK
Form 4 Halozyme Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
Halozyme president & CEO Helen Torley sells $153,390 in stock By Investing.com - Investing.com Nigeria
Halozyme (HALO) CEO sells 1,923 exercised shares under Rule 10b5-1 plan - Stock Titan
How Halozyme’s Leadership Shake-Up Around Drug Delivery At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Sahm
Halozyme Therapeutics focuses on drug-delivery partnerships as investors watch Nasdaq biotech sentim - ad-hoc-news.de
Halozyme Therapeutics (HALO) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Halozyme Therapeutics (HALO) Investor Outlook: Analyzing Growth with 42.20% Revenue Surge - DirectorsTalk Interviews
Halozyme's Q4 earnings miss, higher royalties drive Y/Y revenues - MSN
Halozyme signs collaboration deal with GSK for oncology targets - Investing.com
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued - Sahm
Price to sales forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Halozyme Therapeutics Operating Chief Caudill to Exit - Moomoo
Halozyme announces key executive leadership transition and reorganization - The Globe and Mail
Halozyme stock falls as chief operating officer departs By Investing.com - Investing.com Nigeria
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Halozyme stock falls as chief operating officer departs - Investing.com
Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting - Stock Titan
Halozyme (NASDAQ: HALO) CFO awarded large option and RSU package - Stock Titan
Halozyme (HALO) director sells 1,625 shares in 10b5-1 trades - Stock Titan
Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle - Stock Titan
Halozyme Therapeutics, Inc. Announces Departure of Cortney Caudill as Senior Vice President, Chief Operating Officer - marketscreener.com
Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative? - Sahm
Halozyme names David Ramsay as president drug delivery - Investing.com UK
Halozyme names David Ramsay as president drug delivery By Investing.com - Investing.com South Africa
Halozyme director Mahesh Krishnan sells $547,800 in stock By Investing.com - Investing.com South Africa
Form 4 Halozyme Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia
Halozyme director Mahesh Krishnan sells $547,800 in stock - Investing.com UK
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Jul 08 '26 |
Sale |
79.77 |
1,923 |
153,391 |
767,780 |
| RAMSAY DAVID A | EVP, PRESIDENT, DRUG DELIVERY |
Jun 30 '26 |
Option Exercise |
0.00 |
10,000 |
0 |
10,000 |
| Connaughton Bernadette | Director |
Jul 01 '26 |
Sale |
76.71 |
1,625 |
124,651 |
42,044 |
| Krishnan Mahesh | Director |
Jun 29 '26 |
Option Exercise |
38.46 |
7,304 |
280,912 |
21,766 |
| Krishnan Mahesh | Director |
Jun 29 '26 |
Sale |
75.00 |
7,304 |
547,800 |
14,462 |
0.74%
3.77%
자본화:
|
볼륨(24시간):